Predictive Role of Midtreatment Changes in Survivin, GSTP1, and Topoisomerase 2 alpha Expressions for Pathologic Complete Response to Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer


Eralp Y., Keskin S., Akisik E. E., Akisik E., Igci A., Muslumanoglu M., ...More

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, vol.36, no.3, pp.215-223, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 36 Issue: 3
  • Publication Date: 2013
  • Doi Number: 10.1097/coc.0b013e318243913f
  • Journal Name: AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.215-223
  • Keywords: breast cancer, mRNA, response to neoadjuvant chemotherapy, survivin, GSTP1, topoisomerase 2A, GLUTATHIONE-S-TRANSFERASE, SURGICAL ADJUVANT BREAST, ANTHRACYCLINE-BASED CHEMOTHERAPY, PROJECT PROTOCOL B-27, II-ALPHA, PREOPERATIVE CHEMOTHERAPY, ESOPHAGEAL CANCER, SYSTEMIC THERAPY, TAXOL RESISTANCE, DRUG-RESISTANCE
  • Istanbul University Affiliated: Yes

Abstract

Introduction: The primary aim of this study is to investigate the effect of change in the expression levels of survivin, glutathione-S-transferase P1 (GSTP1), and topoisomerase 2 alpha (TOP2A) on the response to antracyclin-based and taxane-based neoadjuvant chemotherapy.